Thousand Oaks, California-based Amgen Inc. (AMGN) today announced positive results in its ongoing phase III study of using AMG 334 (erenumab) drug for treating episodic migraine.
1 Billion People
Migraine is one of the most incapacitating forms of headache of varying intensity, and is often accompanied by nausea and sensitivity to light and sound. More than 1 billion individuals across the globe are affected by the disease.
More than 90% of migraine patients have episodic migraine, which is characterized by patients having migraine pain for up to 14 days a month. Being the most common form of the illness across a vast global population, episodic migraine offers a big commercial opportunity for medical treatment.
